P/E ratio for Enzo Biochem (ENZB)
P/E ratio as of July 2025 (TTM): -3.24
According to Enzo Biochem's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.24333. At the end of 2019 the company had a P/E ratio of 120.
P/E ratio history for Enzo Biochem from 2001 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2019 | 120 | -1660.97% |
| 2018 | -7.69 | -96.95% |
| 2017 | -252 | -3482.81% |
| 2016 | 7.45 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 RadNet RDNT | -103 | 3,069.58% | 🇺🇸 USA |
 Quest Diagnostics
DGX | 21.0 | -746.40% | 🇺🇸 USA |
 LabCorp LH | 30.0 | -1,025.40% | 🇺🇸 USA |
 Psychemedics PMD | -3.75 | 15.66% | 🇺🇸 USA |
 Qiagen QGEN | 119 | -3,783.00% | 🇳🇱 Netherlands |
 NeoGenomics
NEO | -8.61 | 165.36% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.